According to filings with the U.S. Securities and Exchange Commission, selectION Therapeutics is raising $11,809,601.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Steve Zaniboni played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About selectION Therapeutics
selectION, Inc. is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases and selected cancer indications by targeting autoreactive, chronically activated T cells. The Company has established an efficient, unique technology platform to develop potent and highly selective peptide blockers for ion channels involved in various diseases. The platform enables to systematically optimize target selectivity, providing the opportunity to develop drugs with significantly improved efficacy and safety profiles. selectION is backed by SDL Ventures and Global Source Ventures. The Company is headquartered in San Diego, CA, USA, and has a subsidiary in Martinsried, Germany.

To learn more about selectION Therapeutics, visit http://selectiontherapeutics.com/

Contact:
Steve Zaniboni, Chief Financial Officer
858-967-8014

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.